Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease
| Autor: | Lisa I. Backus, Larry A. Mole, Pamela S. Belperio, Troy A. Shahoumian |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male medicine.medical_specialty Cirrhosis Sustained Virologic Response medicine.medical_treatment Liver transplantation Gastroenterology Antiviral Agents Severity of Illness Index Cohort Studies 03 medical and health sciences Liver disease Young Adult 0302 clinical medicine Internal medicine medicine Humans 030212 general & internal medicine Aged Aged 80 and over Hepatology business.industry Mortality rate Hazard ratio Hepatitis C Hepatitis C Chronic Middle Aged medicine.disease Hepatocellular carcinoma 030211 gastroenterology & hepatology Female business |
| Zdroj: | Hepatology (Baltimore, Md.). 68(3) |
| ISSN: | 1527-3350 |
| Popis: | The impact of sustained virologic response (SVR) on mortality after direct-acting antiviral (DAA) treatment is not well documented in patients without advanced liver disease and affects access to treatment. This study evaluated the impact of SVR achieved with interferon-free DAA treatment on all-cause mortality in hepatitis C virus-infected patients without advanced liver disease. This observational cohort analysis was comprised of 103,346 genotype 1, 2, and 3, hepatitis C virus-monoinfected patients without advanced liver disease, defined by FIB-4 ≤3.25 and no diagnosis of cirrhosis, hepatic decompensation, or hepatocellular carcinoma or history of liver transplantation, identified from the Veterans Affairs Hepatitis C Clinical Case Registry. Among 40,664 patients treated with interferon-free DAA regimens, 39,374 (96.8%) achieved SVR and 1,290 (3.2%) patients were No SVR; 62,682 patients constituted the untreated cohort. The mortality rate for SVR patients of 1.18 deaths/100 patient-years was significantly lower than the rates for both No SVR patients (2.84 deaths/100 patient-years; P < 0.001) and untreated patients (3.84 deaths/100 patient-years; P < 0.001). SVR patients with FIB-4 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text